Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Official Title is A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.

NCT00424047 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00424047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00424047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Official Title is A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
January 1, 2003
Completion date
November 12, 2013
Enrollment
351 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma